About this Interview:
An inspiration and candid conversation between Dr. Mayasari Lim and upcoming 3DHEALS2020 speaker John O’Neil, Chief Scientific Officer of Xylyx, a New York-based startup focusing on creating the perfect cell environment for a variety of biotech process including biofabrication/bioprinting, and tissue engineering. More specifically, Xylyx aims to translate the cell-specific extracellular matrix into biomaterial products with real-world impact. In this short interview, John shared with us his story of co-founding Xylyx, his vision for the future of bioprinting and tissue engineering, and lessons he learned from past successes and failures. John will be speaking with other startup founders and scientists on the Biofabrication Ecosystem panel on June 6th, 2020 at 3DHEALS2020.
Dr. John O’Neill is an expert on biomaterials and tissue- and disease-specific models aimed at transforming drug discovery. He has published extensively in the areas of extracellular matrix (ECM), stem cell research, cell and tissue engineering, regenerative medicine, whole organ recovery and bioengineering, and the use of biomaterials in research, drug discovery and clinical applications. He is an inventor/co-inventor on over 10 issued and pending patents in biotechnology and imaging systems. Dr. O’Neill developed Xylyx Bio’s proprietary platform technology while completing his Ph.D. in Biomedical Engineering at Columbia University in the Laboratory for Stem Cells and Tissue Engineering under Gordana Vunjak-Novakovic, a world leader in tissue engineering, with expertise in regenerative medicine, translational stem cell applications, and disease modeling.